These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 28355398)

  • 21. Impact of calcimimetics in surgery of secondary hyperparathyroidism.
    Ruiz J; Ríos A; Rodríguez JM; Llorente S; Hernández AM; Parrilla P
    Endocrinol Diabetes Nutr; 2017 Jan; 64(1):59-61. PubMed ID: 28440773
    [No Abstract]   [Full Text] [Related]  

  • 22. [Parenteral calcimimetics for the treatment of secondary hyperparathyroidism.].
    Hamano N; Fukagawa M
    Clin Calcium; 2017; 27(4):567-572. PubMed ID: 28336834
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Minimal impact of calcimimetics on the management of hyperparathyroidism in chronic dialysis.
    Brunaud L; Ngueyon Sime W; Filipozzi P; Nomine-Criqui C; Aronova A; Zarnegar R; Kessler M; Frimat L; Ayav C
    Surgery; 2016 Jan; 159(1):183-91. PubMed ID: 26476826
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Effects of Cinacalcet in Older and Younger Patients on Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial.
    Parfrey PS; Drüeke TB; Block GA; Correa-Rotter R; Floege J; Herzog CA; London GM; Mahaffey KW; Moe SM; Wheeler DC; Kubo Y; Dehmel B; Goodman WG; Chertow GM;
    Clin J Am Soc Nephrol; 2015 May; 10(5):791-9. PubMed ID: 25710802
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Economic Evaluation of Cinacalcet in the United States: The EVOLVE Trial.
    Belozeroff V; Chertow GM; Graham CN; Dehmel B; Parfrey PS; Briggs AH
    Value Health; 2015 Dec; 18(8):1079-87. PubMed ID: 26686794
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mortality in dialysis patients with cinacalcet use: A large observational registry study.
    Friedl C; Reibnegger G; Kramar R; Zitt E; Pilz S; Mann JFE; Rosenkranz AR
    Eur J Intern Med; 2017 Jul; 42():89-95. PubMed ID: 28499709
    [TBL] [Abstract][Full Text] [Related]  

  • 27. EARLIER: an observational study to evaluate the use of cinacalcet in incident hemodialysis patients with secondary hyperparathyroidism in daily clinical practice.
    Hemetsberger M; Oberbauer R; Erb H; Pronai W
    Wien Med Wochenschr; 2015 Oct; 165(19-20):410-8. PubMed ID: 26302869
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tolerance and efficacy of a low dose of the calcimimetic agent cinacalcet in controlling moderate to severe secondary hyperparathyroidism in hemodialysis patients.
    Bashir SO; Omer HA; Aamer MA; Somialy R; Morsy MD
    Saudi J Kidney Dis Transpl; 2015 Nov; 26(6):1135-41. PubMed ID: 26586050
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The use of cinacalcet hinders the diagnosis of parathyroid carcinoma in a chronic dialysis patient: a case report.
    Takada D; Tsukamoto T; Fuse M; Kada S; Yanagita M
    BMC Nephrol; 2017 Oct; 18(1):315. PubMed ID: 29047366
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cinacalcet versus Parathyroidectomy in the Treatment of Secondary Hyperparathyroidism Post Renal Transplantation.
    Soliman AR; Maamoun HA; Soliman MA; Darwish H; Elbanna E
    Rom J Intern Med; 2016 Sep; 54(3):184-189. PubMed ID: 27658167
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cinacalcet improves control of secondary hyperparathyroidism in peritoneal dialysis: a multicenter study.
    Portolés J; López-Sánchez P; Bajo MA; Castellano I; del Peso G; Rodríguez JR; Ribera M; Ortigosa A; Selgas R
    Perit Dial Int; 2012; 32(2):208-11. PubMed ID: 22383721
    [No Abstract]   [Full Text] [Related]  

  • 32. Effect of cinacalcet cessation on hyperparathyroidism in kidney transcaplant patients after long-term dialysis therapy.
    Nakai K; Fujii H; Yoshikawa M; Kono K; Yonekura Y; Goto S; Ishimura T; Takeda M; Fujisawa M; Nishi S
    Clin Exp Nephrol; 2015 Dec; 19(6):1184-8. PubMed ID: 25782729
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effects of cinacalcet treatment on bone mineral metabolism, anemia parameters, left ventricular mass index and parathyroid gland volume in hemodialysis patients with severe secondary hyperparathyroidism.
    Torun D; Yildiz I; Micozkadioglu H; Nursal GN; Yigit F; Ozelsancak R
    Saudi J Kidney Dis Transpl; 2016 Jan; 27(1):15-22. PubMed ID: 26787561
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cinacalcet and Clinical Outcomes in Dialysis.
    Komaba H; Fukagawa M
    Semin Dial; 2015; 28(6):594-603. PubMed ID: 26265359
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Administration of calcimimetics after dialysis: same effectiveness, better gastrointestinal tolerability.
    Esteve Simo V; Moreno-Guzmán F; Martínez Calvo G; Fulquet Nicolas M; Pou Potau M; Macias-Toro J; Duarte-Gallego V; Saurina Sole A; Ramírez-de Arellano Serna M
    Nefrologia; 2015; 35(4):403-9. PubMed ID: 26306967
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Calcimimetics in peritoneal dialysis patients.
    Messa P; Castelnovo C; Scalamogna A
    Contrib Nephrol; 2012; 178():143-149. PubMed ID: 22652729
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Management of secondary hyperparathyroidism: practice patterns and outcomes of cinacalcet treatment with or without active vitamin D in Austria and Switzerland - the observational TRANSIT Study.
    Pronai W; Rosenkranz AR; Bock A; Klauser-Braun R; Jäger C; Pendl G; Hemetsberger M; Lhotta K
    Wien Klin Wochenschr; 2017 May; 129(9-10):317-328. PubMed ID: 28091752
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The clinical course of treated hyperparathyroidism among patients receiving hemodialysis and the effect of cinacalcet: the EVOLVE trial.
    Parfrey PS; Chertow GM; Block GA; Correa-Rotter R; Drüeke TB; Floege J; Herzog CA; London GM; Mahaffey KW; Moe SM; Wheeler DC; Dehmel B; Trotman ML; Modafferi DM; Goodman WG
    J Clin Endocrinol Metab; 2013 Dec; 98(12):4834-44. PubMed ID: 24108314
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Successful Reversal of Furosemide-Induced Secondary Hyperparathyroidism With Cinacalcet.
    Srivastava T; Jafri S; Truog WE; Sebestyen VanSickle J; Manimtim WM; Alon US
    Pediatrics; 2017 Dec; 140(6):. PubMed ID: 29192005
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Effectiveness of Cinacalcet as an Adjunctive Therapy for Hereditary 1,25 Dihydroxyvitamin D3-Resistant Rickets.
    Akıncı A; Dündar İ; Kıvılcım M
    J Clin Res Pediatr Endocrinol; 2017 Jun; 9(2):172-178. PubMed ID: 27796266
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.